CD40 and cancer: Importantly, induction of CD40 signaling on DCs using, for example, agonistic antibodies can substitute for CD4+ T-cell help and directly stimulate a specific CD8+ CTL response [125, 130], highlighting a clear rationale for CD40-based cancer immunotherapy.